Clinical efficacy of aidi injection combined with transcatheter arterial chemoembolization in 108 patients with primary hepatic carcinoma

Objective:To evaluate the efficacy of aidi injection combined with transcatheter arterial ehemo-embolization in patients with primary hepatic carcinoma.Methods:Patients with primary hepatic carcinoma(n=108)were randomly divided into two groups.Patients(n=54) in aidigroup were treated with intravenous aidi injection(60 ml in 500 ml 0.9%NaCl)for 21 days(d 1-21),and combined with transcatheter arterial chemoembolization(HCPT 10 mg,5-FU 500 mg and iodinate oil 10 ml)for 28 days.The control patients(n=46)were treated with transcatheter arterial chemoembolization alone.After 2 circles of 28-day treatment,the therapeutic effects were evaluated.Reasults:In aidi and control groups,the effective rates were 80.4%and 63.0%;the median survival time was 8.34 and 8.21 months;the mean survival time was 12.56 and 9.24months;the half a year survival rate was 89.1% and 84.8%;one year survival rate was 63.4%and 47.8%;and two-year survival rate was 28.3% and 17.4%,respectively.For the initial patients in the two groups,halfvear survival rate was 83.1%,one-year survival rate was 46.2%,and two-year survival rate was 18.5%;for retreated patients,the corresponding rates were 96.2%,77.8% and 33.3%.The AFP decline rate was 69.4% in 29 patients of aidi group,and 54.5% in 21 patients of control group.Conclusion:Aidi injection can enhance the effect of transcatheter arterial chemoembolization,improve the quality of life and prolong the survival time in patients with primary hepatic carcinoma;the efficacy can be improved after repeated treatment.